{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:25:19Z","timestamp":1760300719887,"version":"3.37.3"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The primary objective of this phase I, open-label trial was to assess safety and tolerability of tremelimumab monotherapy and combination therapy with durvalumab in Japanese patients with advanced cancer. Tremelimumab is a fully human monoclonal antibody against CTLA-4 in clinical trials; durvalumab is a monoclonal antibody against PD-L1 for the treatment of bladder and lung cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In part 1, tremelimumab 3 or 10 mg\/kg was given every 4 weeks (Q4W) for 6 doses, and thereafter every 12 weeks until discontinuation (n = 8); subsequently tremelimumab 10 mg\/kg Q4W for 6 doses\/Q12W and thereafter until discontinuation was administered in 41 patients with malignant pleural or peritoneal mesothelioma (MPM). In part 2, tremelimumab 10 mg\/kg (Q4W for 6 doses followed by Q12W for 3 doses) was given in combination with durvalumab 15 mg\/kg (Q4W for 13 doses) in cohort 1 (n = 4). In cohort 2 (n = 6), tremelimumab 1 mg\/kg (Q4W for 4 doses) was given in combination with durvalumab 20 mg\/kg (Q4W for 4 doses followed by 10 mg\/kg Q2W for 22 doses), while in cohort 3 (n = 6), fixed-dose tremelimumab 75 mg Q4W for 4 doses plus durvalumab 1500 mg Q4W for 13 doses was given.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In part 1, no dose-limiting toxicities (DLTs) for tremelimumab 3 or 10 mg\/kg (Q4W for 6 doses\/Q12W thereafter until discontinuation) were observed. Six (75%) patients reported treatment-related adverse events (trAEs). In the MPM dose-expansion cohort, 38 (92.7%) patients reported trAEs. In part 2, one DLT (Grade 4 myasthenia gravis) was reported for tremelimumab 10 mg\/kg (Q4W for 6 doses\/Q12W for 3 doses) plus durvalumab 15 mg\/kg (Q4W for 13 doses). One DLT (Grade 4 hyperglycemia) was reported for tremelimumab 75 mg (Q4W for 4 doses) plus durvalumab 1500 mg (Q4W for 13 doses). Fourteen (87.5%) patients reported trAEs. Tremelimumab demonstrated low immunogenicity; 1 (16.7%) patient developed antidrug antibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Tremelimumab 10 mg\/kg (Q4W\/Q12W), tremelimumab 1 mg\/kg (Q4W) plus durvalumab 20 mg\/kg (Q4W\/10 mg\/kg Q2W), and fixed-dose tremelimumab 75 mg (Q4W) plus durvalumab 1500 mg (Q4W) were safe and tolerable.<\/jats:p>\n                  <jats:p>ClinicalTrials.gov Identifier: NCT02141347 (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02141347)<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac099","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T16:50:45Z","timestamp":1654620645000},"page":"e703-e722","source":"Crossref","is-referenced-by-count":6,"title":["Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-0800","authenticated-orcid":false,"given":"Yutaka","family":"Fujiwara","sequence":"first","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan and Aichi Cancer Center , Nagoya , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Takahashi","sequence":"additional","affiliation":[{"name":"National Hospital Organization Hokkaido Cancer Centre , Sapporo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[{"name":"Hiroshima University Hospital , Hiroshima , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Okayama Rosai Hospital , Okayama , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[{"name":"National Hospital Organization Hokkaido Cancer Centre , Sapporo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Hayama","sequence":"additional","affiliation":[{"name":"AstraZeneca , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Sugeno","sequence":"additional","affiliation":[{"name":"AstraZeneca , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Ueda","sequence":"additional","affiliation":[{"name":"AstraZeneca , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Komuro","sequence":"additional","affiliation":[{"name":"AstraZeneca , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lanasa","sequence":"additional","affiliation":[{"name":"AstraZeneca , Gaithersburg, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakano","sequence":"additional","affiliation":[{"name":"Hyogo College of Medicine Hospital, Hyogo, Japan and Otemae Hospital , Osaka , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"issue":"9","key":"2022090215584339400_CIT0001","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022090215584339400_CIT0002","first-page":"1767","article-title":"Tremelimumab: research and clinical development","volume":"9","author":"Comin-Anduix","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"11","key":"2022090215584339400_CIT0003","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"2022090215584339400_CIT0004","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"2022090215584339400_CIT0005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2022090215584339400_CIT0006","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2147\/DDDT.S162214","article-title":"Safety and efficacy of durvalumab (MEDI4736) in various solid tumors","volume":"12","author":"Yang","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2022090215584339400_CIT0007","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s12885-019-5785-z","article-title":"The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1\/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Cancer"},{"issue":"SUPPl 15","key":"2022090215584339400_CIT0008","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2020.38.15_suppl.4508","article-title":"Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"38","author":"Kelley","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2022090215584339400_CIT0009","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2017.35.15_suppl.3069","article-title":"Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors","volume":"35","author":"Callahan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 10","key":"2022090215584339400_CIT0010","first-page":"x39","article-title":"Abstract 496 - Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC","volume":"29","author":"Rizvi","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 13","key":"2022090215584339400_CIT0011","doi-asserted-by":"crossref","first-page":"CT074","DOI":"10.1158\/1538-7445.AM2019-CT074","article-title":"Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): blood and tissue TMB analysis from MYSTIC, a phase III study of first-line durvalumab \u00b1 tremelimumab vs chemotherapy","volume":"79","author":"Peters","year":"2019","journal-title":"Cancer Res"},{"issue":"2","key":"2022090215584339400_CIT0012","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"suppl 4","key":"2022090215584339400_CIT0013","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.2019.37.4_suppl.481","article-title":"CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC)","volume":"37","author":"Chen","year":"2019","journal-title":"J Clin Oncol"},{"author":"Cancer Registry and Statistics, Cancer Information Service, National Cancer Center","key":"2022090215584339400_CIT0014"},{"issue":"8","key":"2022090215584339400_CIT0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"1","key":"2022090215584339400_CIT0016","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"17","key":"2022090215584339400_CIT0017","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022090215584339400_CIT0018","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2022090215584339400_CIT0019","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"20","key":"2022090215584339400_CIT0020","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"PACIFIC investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2022090215584339400_CIT0021","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"issue":"5","key":"2022090215584339400_CIT0022","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/cas.14003","article-title":"Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors","volume":"110","author":"Fujiwara","year":"2019","journal-title":"Cancer Sci"},{"author":"AstraZeneca.","key":"2022090215584339400_CIT0023"},{"author":"AstraZeneca.","key":"2022090215584339400_CIT0024"},{"issue":"3","key":"2022090215584339400_CIT0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/imt.13.9","article-title":"Tremelimumab: a review of development to date in solid tumors","volume":"5","author":"Tarhini","year":"2013","journal-title":"Immunotherapy"},{"issue":"suppl 15","key":"2022090215584339400_CIT0026","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/jco.2015.33.15_suppl.3042","article-title":"Tremelimumab, a fully human anti-CTLA-4 monoclonal antibody, optimal dosing regimen for patients with unresectable malignant mesothelioma (MM)","volume":"33","author":"Narwal","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2022090215584339400_CIT0027","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/oemed-2017-104298","article-title":"Estimation of the global burden of mesothelioma deaths from incomplete national mortality data","volume":"74","author":"Odgerel","year":"2017","journal-title":"Occup Environ Med"},{"issue":"4","key":"2022090215584339400_CIT0028","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"issue":"35","key":"2022090215584339400_CIT0029","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10272","key":"2022090215584339400_CIT0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"2022090215584339400_CIT0031","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"2022090215584339400_CIT0032","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat Med"},{"issue":"254","key":"2022090215584339400_CIT0033","doi-asserted-by":"crossref","first-page":"254ra128","DOI":"10.1126\/scitranslmed.3008918","article-title":"Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response","volume":"6","author":"Kvistborg","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"2022090215584339400_CIT0034","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.3747\/co.25.3840","article-title":"Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges","volume":"25","author":"Nixon","year":"2018","journal-title":"Curr Oncol"},{"issue":"1","key":"2022090215584339400_CIT0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41423-018-0086-z","article-title":"Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy","volume":"16","author":"Li","year":"2019","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"2022090215584339400_CIT0036","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jamaoncol.2019.2311","article-title":"Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1","volume":"5","author":"Lee","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/9\/e703\/45667859\/oyac099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/9\/e703\/45667859\/oyac099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T16:09:27Z","timestamp":1662134967000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/9\/e703\/6603867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,6,7]]},"published-print":{"date-parts":[[2022,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac099","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,6,7]]}}}